Wegovy GLP-1 receptor agonist only Average weight loss of approximately 1315% in clinical trials In head-to-head comparison, semaglutide achieved 13.7% mean weight loss at 72 weeks Often better tolerated for some individuals Zepbound Dual GIP and GLP-1 receptor agonist Average weight loss of 1521% , depending on dose 5 mg: ~15% 10 mg: ~19.5% 15 mg: ~21% In head-to-head comparison, tirzepatide achieved 20.2% mean weight loss at 72 weeks This does not mean Zepbound is universally superior
The clinical flexibility continues with Foundayo (orforglipron), a new oral GLP-1 option without meal restrictions and Zepbound (tirzepatide), which ensures enhanced weight loss results by targeting two hormones
It can help you stick to a calorie reduction diet
Step 4: gradual dose adjustments Doses are typically increased slowly to reduce digestive discomfort
Keep in mind that weight loss is a gradual process, and staying patient and committed will bring the best results
Semaglutide distribution is limited to discrete brain regions, with some differences compared with liraglutide, i.e., in the PVH and LSc